store at low temperature | store at -80°C
Olaratumab(IMC-3G3) 是一种人源抗血小板衍生生长因子受体α (PDGFRα)单克隆 IgG1 抗体,具有抗肿瘤作用,可用于研究晚期软组织肉瘤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 3,190 | 现货 | ||
5 mg | ¥ 7,880 | 现货 | ||
10 mg | ¥ 10,800 | 现货 | ||
25 mg | ¥ 15,900 | 现货 | ||
50 mg | ¥ 21,700 | 现货 | ||
100 mg | ¥ 29,300 | 现货 |
产品描述 | Olaratumab(IMC-3G3) is a human monoclonal IgG1 antibody against platelet-derived growth factor receptor alpha (PDGFRα), which has antitumor effects and can be used to study advanced soft tissue sarcomas. |
体外活性 | In SKOV3-ip1 cells, IMC-3G3 (Olaratumab) at a concentration of 100 μg/mL for 72 hours blocked the phosphorylation of PDGFRα. Furthermore, the combination of IMC-3G3 with docetaxel notably induced apoptosis in SKOV3-ip1 and HeyA8 cell lines [1]. |
体内活性 | IMC-3G3 ( Olaratumab ) ( i.p., 40 mg / kg, three times per week, 6 weeks ) In SKOV3-ip1 tumor-bearing mice, IMC-3G3 alone had no significant anti-tumor effect compared with the control group. In HeyA8 tumor-bearing mice, IMC-3G3 monotherapy showed a significant anti-tumor effect compared with the control group, with a tumor reduction rate of 62 % [ 1 ]. |
别名 | LY3012207, IMC-3G3 |
分子量 | N/A |
CAS No. | 1024603-93-7 |
store at low temperature | store at -80°C
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Olaratumab 1024603-93-7 Angiogenesis Tyrosine Kinase/Adaptors PDGFR LY-3012207 LY3012207 LY 3012207 IMC-3G3 Inhibitor inhibitor inhibit